Introduction: The use of novel kidney injury biomarkers has been shown to improve diagnostic assessment and prognostic prediction in various populations with acute kidney injury (AKI), but their use in a standard clinical practice have been rarely reported. Methods: We reported the clinical implementation of neutrophil gelatinase-associated lipocalin (NGAL) measurement for routine AKI diagnostic workup of patients receiving nephrology consultation in a tertiary academic centre. Specific focus was made on the diagnostic performance to discriminate functional (“pre-renal”) from intra-renal AKI and to predict AKI progression. Results: Forty-five urine NGAL (uNGAL) and 25 plasma NGAL (pNGAL) samples in the first 50 consecutive patients were analysed. KDIGO Stage 1, 2, 3 AKI, and renal replacement therapy occurred in 10%, 40%, 50%, and 24% of cases, respectively. The uNGAL was lower in patients with transient AKI (<48 h) and no sign of urinary tract infections (37 [25–167] ng/mL) than sustained or progressive AKI (298 [74–1,308] ng/mL) (p = 0.016), while pNGAL did not discriminate transient (264 [100–373] ng/mL) from persistent AKI (415 [220–816] ng/mL) (p = 0.137). The median uNGAL level was 63 (35–1,123) ng/mL for functional/pre-renal AKI and 451 (177–1,315) ng/mL for intra-renal AKI (p = 0.043), while the pNGAL was 264 (114–468) and 415 (230–816) ng/mL (p = 0.235), respectively. Conclusion: NGAL, as part of the routine workup, is useful for diagnostic and prognostic assessment of new-onset AKI in clinical practice. Interpretation of an increased NGAL level should be clinically evaluated in its clinical context, particularly considering concomitant infection (urinary or systemic). Clinical adoption of emerging AKI biomarkers as diagnostic tests in clinical practice should be further encouraged.

1.
Coca
SG
,
Yusuf
B
,
Shlipak
MG
,
Garg
AX
,
Parikh
CR
.
Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis
.
Am J Kidney Dis
.
2009
;
53
(
6
):
961
73
. .
2.
Wang
HE
,
Muntner
P
,
Chertow
GM
,
Warnock
DG
.
Acute kidney injury and mortality in hospitalized patients
.
Am J Nephrol
.
2012
;
35
(
4
):
349
55
. .
3.
Hoste
EA
,
Bagshaw
SM
,
Bellomo
R
,
Cely
CM
,
Colman
R
,
Cruz
DN
,
Epidemiology of acute kidney injury in critically ill patients: The Multinational AKI-EPI Study
.
Intensive Care Med
.
2015
;
41
(
8
):
1411
23
. .
4.
Murray
PT
,
Mehta
RL
,
Shaw
A
,
Ronco
C
,
Endre
Z
,
Kellum
JA
,
Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th acute dialysis quality initiative consensus conference
.
Kidney Int
.
2014
;
85
(
3
):
513
21
. .
5.
Meersch
M
,
Schmidt
C
,
Hoffmeier
A
,
Van Aken
H
,
Wempe
C
,
Gerss
J
,
Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
.
Intensive Care Med
.
2017
;
43
(
11
):
1551
61
.
6.
Gocze
I
,
Jauch
D
,
Gotz
M
,
Kennedy
P
,
Jung
B
,
Zeman
F
,
Biomarker-guided intervention to prevent acute kidney injury after major surgery: the Prospective Randomized BigpAK Study
.
Ann Surg
.
2018
;
267
(
6
):
1013
20
.
7.
Berdugo
MA
,
Kirson
NY
,
Zimmer
L
,
Beyhaghi
H
,
Toback
S
,
Scarpati
LM
,
Economic and clinical benefits of early identification of acute kidney injury using a urinary biomarker
.
J Med Econ
.
2019
;
22
(
12
):
1281
9
. .
8.
Guzzi
LM
,
Bergler
T
,
Binnall
B
,
Engelman
DT
,
Forni
L
,
Germain
MJ
,
Clinical use of [TIMP-2]*[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel
.
Crit Care
.
2019 Jun
;
23
(
1
):
225
.
9.
Doi
K
,
Nishida
O
,
Shigematsu
T
,
Sadahiro
T
,
Itami
N
,
Iseki
K
,
The Japanese clinical practice guideline for acute kidney injury 2016
.
J Intensive Care
.
2018
;
6
:
48
. .
10.
Ostermann
M
,
Zarbock
A
,
Goldstein
S
,
Kashani
K
,
Macedo
E
,
Murugan
R
,
Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement
.
JAMA Netw Open
.
2020
;
3
(
10
):
e2019209
. .
11.
Kellum
JA
,
Lameire
N
;
KDIGO AKI Guideline Work Group
.
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary
.
Crit Care
.
2013
;
17
(
1
):
204
.
12.
Arthur
JM
,
Hill
EG
,
Alge
JL
,
Lewis
EC
,
Neely
BA
,
Janech
MG
,
Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery
.
Kidney Int
.
2014
;
85
(
2
):
431
8
. .
13.
Koyner
JL
,
Coca
SG
,
Thiessen-Philbrook
H
,
Patel
UD
,
Shlipak
MG
,
Garg
AX
,
Urine biomarkers and perioperative acute kidney injury: the impact of preoperative estimated GFR
.
Am J Kidney Dis
.
2015
;
66
(
6
):
1006
14
. .
14.
Klein
SJ
,
Brandtner
AK
,
Lehner
GF
,
Ulmer
H
,
Bagshaw
SM
,
Wiedermann
CJ
,
Biomarkers for prediction of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis
.
Intensive Care Med
.
2018
;
44
(
3
):
323
36
. .
15.
Greenberg
JH
,
Zappitelli
M
,
Jia
Y
,
Thiessen-Philbrook
HR
,
de Fontnouvelle
CA
,
Wilson
FP
,
Biomarkers of AKI progression after pediatric cardiac surgery
.
J Am Soc Nephrol
.
2018
;
29
(
5
):
1549
56
. .
16.
Belcher
JM
,
Sanyal
AJ
,
Peixoto
AJ
,
Perazella
MA
,
Lim
J
,
Thiessen-Philbrook
H
,
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury
.
Hepatology
.
2014
;
60
(
2
):
622
32
. .
17.
Zhou
F
,
Luo
Q
,
Wang
L
,
Han
L
.
Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis
.
Eur J Cardiothorac Surg
.
2016
;
49
(
3
):
746
55
. .
18.
Parikh
A
,
Rizzo
JA
,
Canetta
P
,
Forster
C
,
Sise
M
,
Maarouf
O
,
Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney injury (AKI) diagnosis
.
PLoS One
.
2017
;
12
(
5
):
e0178091
.
19.
Ho
J
,
Tangri
N
,
Komenda
P
,
Kaushal
A
,
Sood
M
,
Brar
R
,
Urinary, plasma, and serum biomarkers’ utility for predicting acute kidney injury associated with cardiac surgery in adults: a meta-analysis
.
Am J Kidney Dis
.
2015
;
66
(
6
):
993
1005
. .
20.
Jaques
DA
,
Spahr
L
,
Berra
G
,
Poffet
V
,
Lescuyer
P
,
Gerstel
E
,
Biomarkers for acute kidney injury in decompensated cirrhosis: a Prospective Study
.
Nephrology
.
2019
;
24
(
2
):
170
80
. .
21.
Huelin
P
,
Solà
E
,
Elia
C
,
Solé
C
,
Risso
A
,
Moreira
R
,
Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a Prospective Study
.
Hepatology
.
2019
;
70
(
1
):
319
33
. .
22.
Phan Thai
H
,
Hoang Bui
B
,
Hoang Anh
T
,
Huynh Van
M
.
Value of plasma NGAL and creatinine on first day of admission in the diagnosis of cardiorenal syndrome type 1
.
Cardiol Res Pract
.
2020
;
2020
:
2789410
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.